Overview

Erenumab for Idiosyncratic Facial Pain

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or radiographic evidence of sinusitis.

Phase:

Phase 4

Details

Lead Sponsor:

David Jang, M.D.
Duke University

Collaborator:

Amgen

Treatments:

Antibodies, Monoclonal
Erenumab